{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T12:45:34Z","timestamp":1762087534199,"version":"build-2065373602"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T00:00:00Z","timestamp":1682553600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T00:00:00Z","timestamp":1682553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The injection of morphine from morphine sulfate capsules containing sustained-release microbeads (Skenan\u00ae) is a practice frequently described by French intravenous opioid users. They seek an injectable form of substitution for heroin. Depending on how the syringe is prepared, the morphine rates may vary. The dosage of the capsule, the temperature of the dissolving water and the type of filter used have been identified as the parameters most likely to influence the final quantity of morphine in solution before intravenous injection. The aim of our study was to determine the amounts of morphine actually injected, according to the different preparation modalities described by people who inject morphine and the harm reduction equipment made available to them.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Different morphine syringes were prepared by varying the dosage of the capsule (100 or 200\u00a0mg), the temperature of the dissolving water before adding morphine, ambient (\u2248\u200922\u00a0\u00b0C) or heat (\u2248\u200980\u00a0\u00b0C) and four filtration devices: risk reduction Steribox\u00ae cotton, risk reduction filter \u201cSterifilt\u00ae\u201d, \u201cWheel\u201d filter and cigarette filter. The quantification of the morphine in the syringe body was carried out by liquid phase chromatography coupled with a mass spectrometry detector.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The best extraction yields were obtained with heated water, independently of dosages (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01). Yields of 100\u00a0mg capsules varied according to the filter (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01) and the water temperature (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01), with maximum yields obtained for solutions dissolved in heated water, then filtered with the \u201cWheel\u201d filter (83\u00a0mg). The yields of the 200\u00a0mg capsules varied according to the temperature of the water (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01), without difference according to the filter used (<jats:italic>p<\/jats:italic>\u2009&gt;\u20090.01), and maximum yields obtained for solutions dissolved in heated water (95\u00a0mg).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>No procedure for dissolving Skenan\u00ae led to the complete dissolution of the morphine it contains. Whatever the variations in preparation conditions, the extraction rates of the 200\u00a0mg morphine capsules were lower than those of 100\u00a0mg, without the risk reduction filters adversely impacting morphine extraction. Offering an injectable substitution to persons who inject morphine would make it possible to reduce the risks and damage, particularly overdoses, associated with variations in dosage due to preparation methods.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12954-023-00781-2","type":"journal-article","created":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T10:03:27Z","timestamp":1682589807000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Intravenous misuse of slow-release oral morphine capsules: how much morphine is injected?"],"prefix":"10.1186","volume":"20","author":[{"given":"C\u00e9lian","family":"Bertin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edouard","family":"Montigne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Teixeira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florent","family":"Ferrer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louis","family":"Lauwerie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Damien","family":"Richard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Authier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,4,27]]},"reference":[{"issue":"10208","key":"781_CR1","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1016\/S0140-6736(19)32229-9","volume":"394","author":"L Degenhardt","year":"2019","unstructured":"Degenhardt L, Grebely J, Stone J, Hickman M, Vickerman P, Marshall BDL, et al. Global patterns of opioid use and dependence: harms to populations, interventions, and future action. Lancet. 2019;394(10208):1560\u201379.","journal-title":"Lancet"},{"issue":"1","key":"781_CR2","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1002\/ejp.1291","volume":"23","author":"C Chenaf","year":"2019","unstructured":"Chenaf C, Kabor\u00e9 JL, Delorme J, Pereira B, Mulliez A, Zenut M, et al. Prescription opioid analgesic use in France: trends and impact on morbidity-mortality. Eur J Pain Lond Engl. 2019;23(1):124\u201334.","journal-title":"Eur J Pain Lond Engl"},{"issue":"1","key":"781_CR3","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1192\/j.eurpsy.2021.2219","volume":"64","author":"M Pierce","year":"2021","unstructured":"Pierce M, van Amsterdam J, Kalkman GA, Schellekens A, van den Brink W. Is Europe facing an opioid crisis like the United States? An analysis of opioid use and related adverse effects in 19 European countries between 2010 and 2018. Eur Psychiatry. 2021;64(1):e47.","journal-title":"Eur Psychiatry"},{"issue":"1","key":"781_CR4","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s40264-021-01124-5","volume":"45","author":"J Perri-Pland\u00e9","year":"2022","unstructured":"Perri-Pland\u00e9 J, Miremont-Salam\u00e9 G, Micallef J, Herman C, Baumevieille M, Abriat F, et al. A 13-year national monitoring study to assess narcotic prescriptions and indications (2007\u20132019). Drug Saf. 2022;45(1):37\u201344.","journal-title":"Drug Saf"},{"issue":"2","key":"781_CR5","doi-asserted-by":"publisher","first-page":"113","DOI":"10.2515\/therapie\/2015009","volume":"70","author":"E Jouanjus","year":"2015","unstructured":"Jouanjus E, Gibaja V, Kahn JP, Haramburu F, Daveluy A. Comment identifier un signal en addictovigilance? Therapies. 2015;70(2):113\u201322.","journal-title":"Therapies"},{"issue":"4","key":"781_CR6","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.therap.2017.01.010","volume":"72","author":"E Frauger","year":"2017","unstructured":"Frauger E, Pochard L, Boucherie Q, Giocanti A, Chevallier C, Daveluy A, et al. Dispositif pharmaco\u00e9pid\u00e9miologique de surveillance des substances psychoactives: int\u00e9r\u00eats du programme national OPPIDUM du R\u00e9seau fran\u00e7ais d\u2019addictovigilance. Therapies. 2017;72(4):491\u2013501.","journal-title":"Therapies"},{"key":"781_CR7","unstructured":"Cadet-Ta\u00efrou A, Gandilhon M, Toufik A, Evrard I. Ph\u00e9nom\u00e8nes \u00e9mergents li\u00e9s aux drogues en 2005\u2014Septi\u00e8me rapport national du dispositif TREND. OFDT [Internet]. Saint-Denis: OFDT; 2007. Available from: http:\/\/www.ofdt.fr\/publications\/collections\/rapports\/rapports-d-etudes\/rapports-detudes-ofdt-parus-en-2007\/phenomenes-emergents-lies-aux-drogues-en-2005-septieme-rapport-national-du-dispositif-trend-janvier-2007\/. Archived at www.webcitation.org\/6w6KEplam."},{"issue":"5","key":"781_CR8","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1159\/000346179","volume":"19","author":"H Peyriere","year":"2013","unstructured":"Peyriere H, Eiden C, Micallef J, Lapeyre-Mestre M, Faillie JL, Blayac JP. Slow-release oral morphine sulfate abuse: results of the postmarketing surveillance systems for psychoactive prescription drug abuse in France. Eur Addict Res. 2013;19(5):235\u201344.","journal-title":"Eur Addict Res"},{"issue":"5","key":"781_CR9","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1111\/fcp.12210","volume":"30","author":"H Peyriere","year":"2016","unstructured":"Peyriere H, Nogue E, Eiden C, Frauger E, Charra M, Picot MC, et al. Evidence of slow-release morphine sulfate abuse and diversion: epidemiological approaches in a French administrative area. Fundam Clin Pharmacol. 2016;30(5):466\u201375.","journal-title":"Fundam Clin Pharmacol"},{"key":"781_CR10","unstructured":"Cadet-Ta\u00efrou A, Gandilhon M. Morphine sulphate consumption by French drug users: recent trends (2012\u20132013). [Internet]. Saint Denis: OFDT; 2014 Jul. Available from: https:\/\/bdoc.ofdt.fr\/doc_num.php?explnum_id=20011. Archived at http:\/\/www.webcitation.org\/71iPBwMWQ."},{"key":"781_CR11","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1111\/bcp.14082","volume":"86","author":"C Bertin","year":"2019","unstructured":"Bertin C, Delorme J, Riquelme M, Peyri\u00e8re H, Brousse G, Eschalier A, et al. Risk assessment of using off-label morphine sulfate in a population-based retrospective cohort of opioid-dependent patients. Br J Clin Pharmacol. 2019;86:2338\u201348.","journal-title":"Br J Clin Pharmacol"},{"key":"781_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fpsyt.2022.893590","volume":"13","author":"C Bertin","year":"2022","unstructured":"Bertin C, Bezin J, Chenaf C, Delorme J, Kerckhove N, Pariente A, et al. Oral morphine as an alternative substitution treatment for opioid use disorder, a rare but non-risk-free use. Front Psychiatry. 2022;13:1\u201312. https:\/\/doi.org\/10.3389\/fpsyt.2022.893590.","journal-title":"Front Psychiatry"},{"issue":"59","key":"781_CR13","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.drugpo.2018.06.013","volume":"1","author":"P Roux","year":"2018","unstructured":"Roux P, Mezaache S, Briand-Madrid L, Debrus M, Khatmi N, Maradan G, et al. Profile, risk practices and needs of people who inject morphine sulfate: results from the ANRS-AERLI study. Int J Drug Policy. 2018;1(59):3\u20139.","journal-title":"Int J Drug Policy"},{"issue":"5","key":"781_CR14","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.pharma.2009.06.001","volume":"67","author":"P Chappard","year":"2009","unstructured":"Chappard P. La substitution aux opiac\u00e9s: le point de vue des usagers. Ann Pharm Fr. 2009;67(5):365\u20138.","journal-title":"Ann Pharm Fr"},{"key":"781_CR15","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.drugalcdep.2018.01.036","volume":"187","author":"C Pont\u00e9","year":"2018","unstructured":"Pont\u00e9 C, Lepelley M, Boucherie Q, Mallaret M, Lapeyre Mestre M, Pradel V, et al. Doctor shopping of opioid analgesics relative to benzodiazepines: a pharmacoepidemiological study among 11.7 million inhabitants in the French countries. Drug Alcohol Depend. 2018;187:88\u201394.","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"781_CR16","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1111\/fcp.12356","volume":"32","author":"E Jouanjus","year":"2018","unstructured":"Jouanjus E, Guernec G, Lapeyre-Mestre M, French Addictovigilance N. Medical prescriptions falsified by the patients: a 12-year national monitoring to assess prescription drug diversion. Fundam Clin Pharmacol. 2018;32(3):306\u201322.","journal-title":"Fundam Clin Pharmacol"},{"key":"781_CR17","unstructured":"Injection de Skenan en photos\u2014PsychoWiki, le wiki de Psychoactif [Internet]. [cited 2022 Mar 11]. Available from: https:\/\/www.psychoactif.org\/psychowiki\/index.php?title=Injection_de_Skenan_en_photos."},{"issue":"12","key":"781_CR18","doi-asserted-by":"publisher","first-page":"e113991","DOI":"10.1371\/journal.pone.0113991","volume":"9","author":"R Bouqui\u00e9","year":"2014","unstructured":"Bouqui\u00e9 R, Wainstein L, Pilet P, Mussini JM, Deslandes G, Clouet J, et al. Crushed and injected buprenorphine tablets: characteristics of princeps and generic solutions. PLoS ONE. 2014;9(12):e113991.","journal-title":"PLoS ONE"},{"issue":"6","key":"781_CR19","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/1477-7517-6-37","volume":"22","author":"S McLean","year":"2009","unstructured":"McLean S, Bruno R, Brandon S, de Graaff B. Effect of filtration on morphine and particle content of injections prepared from slow-release oral morphine tablets. Harm Reduct J. 2009;22(6):37.","journal-title":"Harm Reduct J"},{"issue":"1","key":"781_CR20","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12954-020-00389-w","volume":"17","author":"L Keijzer","year":"2020","unstructured":"Keijzer L. Reducing harm through the development of good preparation practices for the injection of slow release morphine sulphate capsules. Harm Reduct J. 2020;17(1):48.","journal-title":"Harm Reduct J"},{"issue":"17","key":"781_CR21","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12954-020-00389-w","volume":"16","author":"L Keijzer","year":"2020","unstructured":"Keijzer L. Reducing harm through the development of good preparation practices for the injection of slow release morphine sulphate capsules. Harm Reduct J. 2020;16(17):48.","journal-title":"Harm Reduct J"},{"key":"781_CR22","unstructured":"Les diff\u00e9rents filtres pour l\u2019injection: avantages et inconv\u00e9nients\u2014PsychoWiki, le wiki de Psychoactif [Internet]. Available from: https:\/\/www.psychoactif.org\/psychowiki\/index.php?title=Les_diff%C3%A9rents_filtres_pour_l%27injection_:_avantages_et_inconv%C3%A9nients."},{"key":"781_CR23","unstructured":"Sterifilt, pr\u00e9sentation [Internet]. [cited 2022 Aug 17]. Available from: https:\/\/www.apothicom.org\/sterifilt-presentation.htm."},{"key":"781_CR24","unstructured":"Filtres Antibact\u00e9riens [Internet]. [cited 2022 Aug 17]. Available from: https:\/\/www.apothicom.org\/filtresantibacteriens.htm."},{"key":"781_CR25","doi-asserted-by":"crossref","unstructured":"Felton LA, McGinity JW, McGinity JW. Chapter 2: Aqueous polymeric coating for modified release oral dosage forms. In: Aqueous polymeric coatings for pharmaceutical dosage forms [Internet]. CRC Press; 2008, p. 47\u201366. Available from: https:\/\/www.taylorfrancis.com\/books\/e\/9780429119446.","DOI":"10.3109\/9780849387883"},{"issue":"11","key":"781_CR26","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1016\/j.bulcan.2018.06.011","volume":"105","author":"N Michenot","year":"2018","unstructured":"Michenot N, Rostaing S, Baron L, Faure S, Jovenin N, Hubault P, et al. La morphine dans le cadre du changement d\u2019opio\u00efdes ou de voie d\u2019administration, chez l\u2019adulte avec une douleur due au cancer. Bull Cancer (Paris). 2018;105(11):1052\u201373.","journal-title":"Bull Cancer (Paris)"},{"key":"781_CR27","first-page":"1313","volume-title":"The Merck index: an encyclopedia of chemicals and drugs","year":"1976","unstructured":"Windholz M, editor. The Merck index: an encyclopedia of chemicals and drugs. 9th ed. Rahway: Merck; 1976. p. 1313.","edition":"9"},{"issue":"8","key":"781_CR28","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/1477-7517-8-20","volume":"22","author":"L Keijzer","year":"2011","unstructured":"Keijzer L, Imbert E. The filter of choice: filtration method preference among injecting drug users. Harm Reduct J. 2011;22(8):20.","journal-title":"Harm Reduct J"},{"issue":"7","key":"781_CR29","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1111\/add.12930","volume":"110","author":"S Darke","year":"2015","unstructured":"Darke S, Duflou J, Torok M. The health consequences of injecting tablet preparations: foreign body pulmonary embolization and pulmonary hypertension among deceased injecting drug users. Addict Abingdon Engl. 2015;110(7):1144\u201351.","journal-title":"Addict Abingdon Engl"},{"key":"781_CR30","unstructured":"Arr\u00eat\u00e9 du 26 janvier 2022 portant approbation du cahier des charges national relatif aux \u00abhaltes \u201csoins addictions\u201d\u00bb [Internet]. Available from: https:\/\/www.legifrance.gouv.fr\/jorf\/id\/JORFTEXT000045207066."},{"key":"781_CR31","unstructured":"Article 43 - LOI n\u00b0 2016-41 du 26 janvier 2016 de modernisation de notre syst\u00e8me de sant\u00e9 (1)\u2014L\u00e9gifrance [Internet]. Available from: https:\/\/www.legifrance.gouv.fr\/loda\/article_lc\/LEGIARTI000044628748\/."},{"key":"781_CR32","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyac120\/6606118","author":"P Roux","year":"2022","unstructured":"Roux P, Jauffret-Roustide M, Donadille C, Briand Madrid L, Denis C, C\u00e9l\u00e9rier I, et al. Impact of drug consumption rooms on non-fatal overdoses, abscesses and emergency department visits in people who inject drugs in France: results from the COSINUS cohort. Int J Epidemiol. 2022. https:\/\/doi.org\/10.1093\/ije\/dyac120\/6606118.","journal-title":"Int J Epidemiol"},{"key":"781_CR33","doi-asserted-by":"publisher","first-page":"108984","DOI":"10.1016\/j.drugalcdep.2021.108984","volume":"227","author":"ML Martins","year":"2021","unstructured":"Martins ML, Wilthagen EA, Oviedo-Joekes E, Beijnen JH, de Grave N, Uchtenhagen A, et al. The suitability of oral diacetylmorphine in treatment-refractory patients with heroin dependence: a scoping review. Drug Alcohol Depend. 2021;227:108984.","journal-title":"Drug Alcohol Depend"},{"issue":"11","key":"781_CR34","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1111\/j.1360-0443.2006.01569.x","volume":"101","author":"U Frick","year":"2006","unstructured":"Frick U, Rehm J, Kovacic S, Ammann J, Uchtenhagen A. A prospective cohort study on orally administered heroin substitution for severely addicted opioid users. Addict Abingdon Engl. 2006;101(11):1631\u20139.","journal-title":"Addict Abingdon Engl"},{"issue":"3","key":"781_CR35","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1159\/000313335","volume":"16","author":"U Frick","year":"2010","unstructured":"Frick U, Rehm J, Zullino D, Fernando M, Wiesbeck G, Ammann J, et al. Long-term follow-up of orally administered diacetylmorphine substitution treatment. Eur Addict Res. 2010;16(3):131\u20138.","journal-title":"Eur Addict Res"},{"key":"781_CR36","doi-asserted-by":"publisher","DOI":"10.2810\/50141","volume-title":"New heroin-assisted treatment\u2014recent evidence and current practices of supervised injectable heroin treatment in Europe and beyond: EMCDDA Insights","author":"European Monitoring Centre for Drugs and Drug Addiction","year":"2012","unstructured":"European Monitoring Centre for Drugs and Drug Addiction. New heroin-assisted treatment\u2014recent evidence and current practices of supervised injectable heroin treatment in Europe and beyond: EMCDDA Insights. LU: Publications Office; 2012. https:\/\/doi.org\/10.2810\/50141."},{"key":"781_CR37","doi-asserted-by":"crossref","unstructured":"Strang L, Taylor J. Heroin-assisted treatment and supervised drug consumption sites: experience from four countries [Internet]. RAND Corporation; 2018. Available from: https:\/\/www.rand.org\/pubs\/working_papers\/WR1262.html.","DOI":"10.7249\/WR1262"},{"issue":"1","key":"781_CR38","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1192\/bjp.bp.106.026112","volume":"191","author":"C Haasen","year":"2007","unstructured":"Haasen C, Verthein U, Degkwitz P, Berger J, Krausz M, Naber D. Heroin-assisted treatment for opioid dependence: randomised controlled trial. Br J Psychiatry. 2007;191(1):55\u201362.","journal-title":"Br J Psychiatry"},{"issue":"4","key":"781_CR39","doi-asserted-by":"publisher","first-page":"606","DOI":"10.17269\/s41997-020-00315-4","volume":"111","author":"N Maghsoudi","year":"2020","unstructured":"Maghsoudi N, Bowles J, Werb D. Expanding access to diacetylmorphine and hydromorphone for people who use opioids in Canada. Can J Public Health Rev Can Sant\u00e9 Publique. 2020;111(4):606\u20139.","journal-title":"Can J Public Health Rev Can Sant\u00e9 Publique"},{"issue":"1","key":"781_CR40","first-page":"1","volume":"2","author":"SD Khangura","year":"2022","unstructured":"Khangura SD, Walter M. Clinical effectiveness of opioid substitution treatment. Can J Health Technol. 2022;2(1):1\u201353.","journal-title":"Can J Health Technol"},{"key":"781_CR41","unstructured":"Haute Autorit\u00e9 de Sant\u00e9. Bon usage des m\u00e9dicaments opio\u00efdes: antalgie, pr\u00e9vention et prise en charge du trouble de l\u2019usage et des surdoses [Internet]. Saint-Denis: Haute Autorit\u00e9 de Sant\u00e9; 2022 [cited 2022 Apr 8]. Available from: https:\/\/www.has-sante.fr\/jcms\/p_3215131\/fr\/bon-usage-des-medicaments-opioides-antalgie-prevention-et-prise-en-charge-du-trouble-de-l-usage-et-des-surdoses."}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-023-00781-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-023-00781-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-023-00781-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T10:05:12Z","timestamp":1682589912000},"score":1,"resource":{"primary":{"URL":"https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-023-00781-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,27]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["781"],"URL":"https:\/\/doi.org\/10.1186\/s12954-023-00781-2","relation":{},"ISSN":["1477-7517"],"issn-type":[{"type":"electronic","value":"1477-7517"}],"subject":[],"published":{"date-parts":[[2023,4,27]]},"assertion":[{"value":"5 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"In accordance with French law, this study is not a research study on human beings and does not require ethical approval.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"59"}}